Drug facts
“Ozempic face” and what the label records
Quick answer
It is not a clinical finding and not a side effect in the label. The word “facial” appears zero times in the full published label, and no trial measured facial appearance. What is documented is weight loss — and fat leaves the face along with the rest of the body.
The term is not clinical1
We searched the whole label. “Facial” does not occur. The phrase itself came from press coverage and from a dermatologist quoted in it, not from a trial, a label or a regulator — which does not make the observation false, but does mean there is no measured rate to give.
What is actually happening1
Substantial weight loss reduces subcutaneous fat, and the face has subcutaneous fat. Losing volume there tends to make lines and hollows more visible, particularly when the loss is large or fast. That is a consequence of the weight change rather than a direct action of the drug, and it is why the same appearance is described after any comparable loss.
Why this drug got the name1
Because semaglutide, as Ozempic, was the drug in wide use when the phrase caught on — not because it does something to the face that other routes to the same weight loss do not. The name is an accident of timing, and it now attaches to a whole drug class.
What this page is not
It is not cosmetic advice and it is not a claim that nothing changes. It reports what the label records, which on this subject is the weight loss itself and nothing about the face.
Sources
- FDA prescribing information for WEGOVY (semaglutide), full label as published on DailyMed, revision 6/2026 — complete text searched (212,786 characters) DailyMed